Physician profile
Glen E Dust
NPI 1477555738
$2,550.71
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $235 · 2021: $736 · 2022: $967 · 2023: $446 · 2024: $55.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $315.23 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $252.16 | 2020-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Novo Nordisk INC | $246.57 | 2021-2023 | Ozempic |
| Amgen INC. | $233.34 | 2019-2023 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $217.22 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $199.16 | 2020-2023 | Xarelto |
| Lilly USA, LLC | $196.29 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $145.62 | 2022-2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $93.42 | 2021-2022 | |
| Amarin Pharma, INC. | $84.67 | 2020-2022 | |
| Pfizer INC. | $81.68 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.53 | 2021-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $64.52 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.54 | 2022-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.17 | 2022-2023 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $39.27 | 2020 | |
| Mylan Specialty L.P. | $38.06 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.66 | 2022 | |
| Glaxosmithkline, LLC. | $30.41 | 2021-2024 | Arexvy, Shingrix |
| Astellas Pharma US INC | $22.21 | 2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $20.19 | 2021 | |
| Abbvie INC. | $17.40 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.77 | 2022 | |
| Tactile Systems Technology INC | $16.46 | 2022 | |
| Daiichi Sankyo INC. | $13.33 | 2019 | |
| Electromed, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Dust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.